Nalaganje...
Response and Resistance to BCR-ABL1-Targeted Therapies
Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine kinase, has served as a paradigm for successful application of molecularly targeted cancer therapy. The development of the tyrosine kinase inhibitor (TKI) imatinib allows patients with CML to experience near-nor...
Shranjeno v:
| izdano v: | Cancer Cell |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7722523/ https://ncbi.nlm.nih.gov/pubmed/32289275 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2020.03.006 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|